Stock info IBA | Filter  Basic-Info

IBA was founded by Yves Jongen in 1986 as a by-product of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve, which developed its primary cyclotron in 1947. The main purpose was to develop an exclusive proficiency in particle accelerator technology to meet uprising needs in medication and manufacturing business. Despite the fact that the company was originally lively in medical imaging, IBA rapidly acknowledged the need to diversify. So, the corporation turned its focus to radiotherapy (Proton Therapy) and developed cyclotrons which enables them to take care of several forms of cancer with a level of meticulousness and effectiveness. IBA builds up, develops and maintains medical devices and software resolution for cancer treatment by proton beam therapy, for cancer analysis and for patient eminence assurance (Dosimetry).

The corporate partners with foremost healthcare companies to offer cancer clinics and academic health centers with a completely incorporated approach of the patient flow. At present, IBA services in oncology are used in approximately 3,000 hospitals globally.
A company's ability in particle accelerators facilitates IBA to offer sterilization and ionization solutions also in the healthcare industry. IBA is headquartered in Belgium, IBA has operations in approximately more than 40 countries across North America, Europe & Asia. IBA is quoted on the pan-European stock exchange EURONEXT. IBA Molecular is a joint venture companionship between IBA and SK Capital Partners in which IBA has possession of a 40% stake.

IBA's mission is to look after, improve and save lives while conquesting over illness and improving health of each patient which is also the objective of every physician and the motivation for all researchers. IBA is having a zealous squad of professionals enthusiastic about developing innovative technologies to cure cancer which affects us all, either directly or indirectly. It takes more than improvement and Research & Development team to deliver primary edge technology for the advantage of the patients. It obliges for zeal and willpower to confront the conventional way of doing things. IBA challenges developing new technologies and strategies and shares thoughts and knowledge with its patrons and partners together with the foremost specialist to develop and distribute tailored solutions to produce enhanced results for the benefit of the patient. In 2012 IBA formed a tactical association with SK Capital Partners to make IBA Molecular Imaging, a jointly-owned companionship resulting from the IBA’s Molecular imaging unit. SK Capital Partners owns a 60 % stake in the company while IBA has the remaining 40%. The decisive objective of the Group is to provide solutions, products and services that will assist its patrons to shield, improve and save lives of people globally leveraging on its turf of knowledge and proficiency with enthusiasm and commitment.